Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies

BACKGROUND: The duration of prior hormonal treatment can predict responses to subsequent therapy in patients with metastatic castration-resistant prostate cancer (mCRPC). OBJECTIVE: To determine if prior endocrine therapy duration is an indicator of abiraterone acetate (AA) sensitivity. DESIGN, SETT...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Eur Urol
Autors principals: Bellmunt, Joaquim, Kheoh, Thian, Yu, Margaret K., Smith, Matthew R., Small, Eric J., Mulders, Peter F.A., Fizazi, Karim, Rathkopf, Dana E., Saad, Fred, Scher, Howard I., Taplin, Mary-Ellen, Davis, Ian D., Schrijvers, Dirk, Protheroe, Andrew, Molina, Arturo, De Porre, Peter, Griffin, Thomas W., de Bono, Johann S., Ryan, Charles J., Oudard, Stéphane
Format: Artigo
Idioma:Inglês
Publicat: 2015
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5465643/
https://ncbi.nlm.nih.gov/pubmed/26508309
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2015.10.021
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars